Federal Circuit Decision Provides Opening for Preparation Methods in Diagnostic Space, But Not for Diagnostic Claims

Mar 17, 2020

Reading Time : 2 min

In 1996, two scientists discovered that maternal plasma and serum, which is usually discarded as medical waste, contain some amount of cell-free fetal DNA that can be used for diagnostic purposes. Those scientists obtained a patent for detecting small fractions of paternally inherited cell-free fetal DNA, which the Federal Circuit invalidated under Section 101 in 2015. Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371, 1373 (Fed. Cir. 2015). The patents in this case are unrelated to the patent in Ariosa, but rely on the same scientific discovery as their foundation. Specifically, the patents acknowledge the discovery, but then identify a technical problem with its application in medicine—namely, that it is very difficult to separate the fetal DNA in maternal plasma and serum from the extracellular DNA derived from the mother.

The inventors of the patents at issue here found a solution to this problem after they realized that fetal DNA and maternal DNA can be distinguished by size. Using that information, the inventors developed methods for preparing samples of fetal DNA through size discrimination, and patented those methods. Illumina, Inc. and Sequenom, Inc. (collectively, “Illumina”) later sued Ariosa Diagnostics, Inc. and others (collectively, “Ariosa”) for infringing two such method patents. Ariosa moved for summary judgment of invalidity under Section 101, which the district court granted based on step one of the Alice test.

On appeal, the Federal Circuit noted that it was undisputed that the inventors discovered a natural phenomenon, but that was not the question before the court. The question was whether the patents claim that natural phenomenon or claim subject matter that exploits the discovery. As to that question, the Federal Circuit determined they did not. The claims here are to a process for preparing and separating DNA samples, i.e., they “achieve[] more than simply observing that fetal DNA is shorter than maternal DNA or detecting the presence of that phenomenon.” As such, they meet the standards for eligibility under step one, leaving no need to address step two.

In distinguishing this case from Ariosa, the court explained the only operative steps in Ariosa involved amplifying DNA and then detecting it. In other words, the inventors in Ariosa discovered the existence of cell-free fetal DNA and then claimed the knowledge that it exists and a method to see it exists. Here, the claims cover more—they cover the process of separating DNA fractions to enrich for a particular type of DNA: “The claimed methods utilize the natural phenomenon that the inventors discovered by employing physical process steps to selectively remove larger fragments of cell-free DNA and thus enrich a mixture in cell-free fetal DNA.”

Judge Reyna dissented from the court’s decision. In his view, the claims at issue here differed little from the claims at issue in Ariosa, and should be held invalid for the same reasoning applied in that case.

We’ll have to wait and see if this decision survives further review. But if it holds, this case may limit the application of Ariosa and provide a much-needed avenue for companies seeking to obtain defensible patent rights in the diagnostics space.

Illumina, Inc. v. Ariosa Diagnostics, Inc., C.A. No. 2019-1419 (Fed. Cir. 2020)

Share This Insight

Previous Entries

IP Newsflash

November 5, 2024

The Federal Circuit vacated a district court’s fee award because the district court considered certain information that was not relevant to the question of whether plaintiff’s case was exceptional. Specifically, the Federal Circuit held that only those “red flags” that related to the successful Section 101 defense, which served as the basis for the district court’s grant of summary judgment, could be used to show the case was fatally flawed.   

...

Read More

IP Newsflash

November 1, 2024

The Federal Circuit’s decision in Kyocera Senco Industrial Tools Inc. v. International Trade Commission articulated a bright-line test for patent expert admissibility: to testify from the perspective of a “person of ordinary skill in the art” (POSITA), the expert must at least meet the definition of a POSITA for the patents-in-suit. Absent that level of skill, Kyocera holds that the witness’s testimony is not sufficiently reliable or relevant enough to be relied on by a fact-finder.

...

Read More

IP Newsflash

October 29, 2024

The PTAB denied a petitioner’s motion to compel routine discovery that sought information from a parallel ITC investigation for alleged inconsistent positions taken by patent owner in the IPR. The board found that patent owner had not taken inconsistent positions but warned patent owner that it had an ongoing duty to produce any information inconsistent with arguments made during the present IPR, even if that information related to arguments patent owner had dropped at the ITC.

...

Read More

IP Newsflash

October 11, 2024

The Central District of California ruled that the heightened pleading standard of Federal Rule of Civil Procedure 9(b) applies to all three prongs of a false patent marking claim, including the third prong, competitive injury. In doing so, took a clear stand on an issue with a nationwide split among district courts.

...

Read More

IP Newsflash

October 10, 2024

In a patent case containing a variety of federal and state law claims, the District of Massachusetts retained supplemental jurisdiction over the state law claims even after all the federal law claims were dismissed.

...

Read More

IP Newsflash

October 3, 2024

The Federal Circuit recently upheld the USPTO’s authority under the estoppel provision 37 C.F.R. § 42.73(d)(3)(i) to prohibit a patent owner from obtaining patent claims that are not patentably distinct from claims previously declared unpatentable in inter partes review (IPR) proceedings. However, the court clarified that the regulation applies only to new claims or amended claims, not previously issued claims.

...

Read More

IP Newsflash

September 27, 2024

In Kyocera Senco Industrial Tools Inc. v. International Trade Commission, the Federal Circuit held that an expert must meet the definition of a “person of ordinary skill in the art” of the asserted patents in order to opine on infringement, among other issues. This new bright-line test and the underlying rationale, however, raised several new questions regarding expert admissibility. SeeFederal Circuit: Narrow Definition of Skill in the Art Dooms Expert’s Testimony” and “Grappling With A Bright-Line Patent Expert Admissibility Test.” The Federal Circuit recently addressed one of those questions, namely whether an expert must have acquired the requisite level of skill as of the time of the invention or whether it is sufficient for an expert to acquire that knowledge at a later date.

...

Read More

IP Newsflash

September 23, 2024

The Director of the USPTO initiated sua sponte review of a PTAB panel’s decision to impose sanctions based on patentee’s conduct during IPR proceedings. The PTAB cancelled all of patentee’s claims, including those not unpatentable on the merits, after finding that patentee deliberately withheld data relevant to the patentability of the claims at issue. In her review, the Director addressed which regulations are implicated upon a party’s misconduct during AIA proceedings and addressed whether entry of judgment in the trial was an appropriate sanction.

...

Read More

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.